Ochsner Translational Medicine Research Initiative (OTMRI)
Initiative Description and Objectives
The primary objective of the Ochsner Translational Medicine Research Initiative (OTMRI) is to promote translational medicine research by Ochsner physicians. This program will provide seed funds to initiate or continue pre-clinical, translational research projects focusing on clinical areas of interest to the institution. To be eligible for an OTMRI grant, the research project must include an Ochsner physician-scientist as the Principal Investigator and one or more external collaborator(s) (local, national or international) with an established and productive research program and a strong record of extramural funding. By funding new or existing projects with the potential for extramural funding, including future NIH grants, OTMRI will allow Ochsner physician-scientists to gain research independence.
The aim of the OTMRI is to facilitate, foster and promote a culture of biomedical research at Ochsner, thereby strengthening research programs and the national reputation of research at our institution. This ultimately will allow Ochsner physicians with strong academic interests to present their work at peer-reviewed, regional and national Society meetings and compete more effectively for extramural funding.
Research Areas of Interest
While research topics in any medical discipline or disease are eligible for this award, priority will be given to those applications focusing on the Institution’s self-identified Centers of Excellence listed below:
- Cardiovascular Disease
- Transplant and Digestive Diseases
- Reproductive Sciences
Applicants and Application Process
An Ochsner physician and a basic research scientist are required as co-investigators. Preferably, one member of the team should have a strong track record in extramural funding and one member should be a promising investigator with potential for extramural funding. The less experienced investigator will identify an experienced investigator who will serve as an advisor/mentor in addition to being a co-investigator.
Submission to this RFA is a two step process. In the initial phase, eligible applicants will submit a Letter of Intent (LOI) following the instructions provided below. LOIs will be evaluated qualitatively by several criteria including alignment with Institutional clinical priorities. LOI’s deemed most responsive to this RFA will be invited to submit a full application.
The LOI template, other application forms and instructions can be found HERE (note: you must be on an Ochsner network in order to access this link).
LOIs and full applications will be reviewed by members of the OTMRI Advisory Committee and, where appropriate, external investigators with subject matter expertise. Proposals will be reviewed for innovation, quality, feasibility, likelihood of future extramural funding, and research foci (strength within the institution). INCOMPLETE AND LATE SUBMISSIONS WILL NOT BE REVIEWED AND NO EXCEPTIONS WILL BE ALLOWED.
All awardees must submit a written report no later than 90 days after termination of the award period summarizing progress made towards the achievement of the originally stated aims, including significant results (positive or negative) and any publications resulting from the conduct of the research. Instructions and forms for the submission of this report will be provided. For awardees who submit a competitive application for continued funding of the project, the application will serve as a progress report. A final report is due after the final award period for the project.
OTMRI Documents and Forms
- Request for Application (includes all due dates)
- Letter of Intent Template (Required)
- Instructions for Full Submission
- Face Page
- Budget Justification
- Facilities, Equipment, & Other Resources
- History of Support
- NIH Biosketch (version B)
- NIH Biosketch Instructions
- Other Information
Please note: The Narrative and the Sustainability Program sections are required, but have no form. See the instructions for full details.
Please direct all questions regarding this initiative to Matt Estrade at email@example.com.